GUELPH, ON / ACCESSWIRE / October 13, 2021 / ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian, nanotechnology company focused on next-gen healthcare solutions, announces that it has submitted an application to list its common stock on The Nasdaq Capital Market® ("Nasdaq") and that it has retained Donohoe Advisory Associates LLC to assist with the listing process. The listing of the Company's common shares on the Nasdaq remains subject to the approval by Nasdaq and the satisfaction of all applicable listing and regulatory requirements.
"This submission marks an important step as we continue to generate additional interest and awareness in the U.S. investment community. We anticipate that a Nasdaq listing will improve liquidity, increase corporate visibility and enhance shareholder value. As an IP development company focused on technologies that improve health and enhance safety, we look forward to joining the ranks of other global life sciences and technology companies listed in the U.S.," commented Greg Fenton, CEO.
About ZEN Graphene Solutions Ltd.
ZEN is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. ZEN is currently focused on commercializing ZENGuardTM, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.The Company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about ZEN Graphene Solutions Ltd., please visit our website at www.ZENGraphene.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.com.